Evommune, Inc.
EVMN
$20.49
$0.301.49%
NYSE
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | 0.00 | 10.00M | 0.00 | 3.00M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | 0.00 | 10.00M | 0.00 | 3.00M |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | 0.00 | 10.00M | 0.00 | 3.00M |
| SG&A Expenses | 6.64M | 9.31M | 3.69M | 3.36M | 3.67M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 23.95M | 29.72M | 23.33M | 22.99M | 18.03M |
| Operating Income | -23.95M | -29.72M | -13.33M | -22.99M | -15.03M |
| Income Before Tax | -21.67M | -28.27M | -12.48M | -13.57M | -14.56M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -21.67M | -28.27M | -12.48M | -13.57M | -14.56M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -21.67M | -28.27M | -12.48M | -13.57M | -14.56M |
| EBIT | -23.95M | -29.72M | -13.33M | -22.99M | -15.03M |
| EBITDA | -23.61M | -29.39M | -13.02M | -22.62M | -14.66M |
| EPS Basic | -0.64 | -1.43 | -8.07 | -8.80 | -9.48 |
| Normalized Basic EPS | -0.40 | -0.89 | -5.05 | -5.50 | -5.93 |
| EPS Diluted | -0.64 | -1.43 | -8.07 | -8.80 | -9.48 |
| Normalized Diluted EPS | -0.40 | -0.89 | -5.05 | -5.50 | -5.93 |
| Average Basic Shares Outstanding | 33.67M | 19.78M | 1.55M | 1.54M | 1.54M |
| Average Diluted Shares Outstanding | 33.67M | 19.78M | 1.55M | 1.54M | 1.54M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |